Some interesting points from the E & P report today:
■ CP-101 for the treatment of hyperphagia in Prader-Willi syndrome (PWS) is being progressed into Phase 3 by Acadia, and
accordingly the company will be ramping up engagement with PWS communities. This creates an obvious synergy with NNZ-2591,
which is also being studied in this indication by NEU. Given the existing commercial relationship, which appears to be on good
terms, as well as the exiting split indication license of NNZ-2591 to Acadia, they are clearly the prime suitor for Neuren's pipeline
asset. VP of commercial operations, Gerry Zhou, commented at the E&P Small Cap conference that whilst Acadia certainly has the
advantage, there are a number of other interested parties, and the process will be competitive.
3
■ Another scenario is that a larger pharmaceutical company (e.g. Biogen, Pfizer) may attempt to acquire both Acadia and Neuren. CEO
Jon Pilcher acknowledged the possibility of an acquisition but noted that the company is not being operated towards that outcome.
- Forums
- ASX - By Stock
- Neuren Media and Analyst Coverage
Some interesting points from the E & P report today:■ CP-101 for...
- There are more pages in this discussion • 456 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.06 |
Change
-0.140(0.73%) |
Mkt cap ! $2.433B |
Open | High | Low | Value | Volume |
$18.76 | $19.35 | $18.71 | $7.893M | 414.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 5037 | $19.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.16 | 881 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 5037 | 19.000 |
1 | 881 | 18.990 |
1 | 922 | 18.970 |
1 | 881 | 18.960 |
1 | 881 | 18.930 |
Price($) | Vol. | No. |
---|---|---|
19.160 | 881 | 1 |
19.190 | 2069 | 3 |
19.220 | 881 | 1 |
19.250 | 881 | 1 |
19.330 | 200 | 1 |
Last trade - 16.10pm 01/05/2024 (20 minute delay) ? |
|
|||||
Last
$19.11 |
  |
Change
-0.140 ( 0.78 %) |
|||
Open | High | Low | Volume | ||
$18.80 | $19.34 | $18.73 | 92009 | ||
Last updated 15.59pm 01/05/2024 ? |
Featured News
NEU (ASX) Chart |
The Watchlist
BPH
BPH ENERGY LTD
David Breeze, MD & Executive Chairman
David Breeze
MD & Executive Chairman
SPONSORED BY The Market Online